Latest news, press releases, and SEC filings for Inhibrx Biosciences Inc (INBX) https://caymanjournal.com/stock/INBX en-us Copyright 2026, Cayman Journal editorial@caymanjournal.com (Editorial Team) webmaster@caymanjournal.com (Web Master) Tue, 28 Apr 2026 00:10:27 GMT 60 https://caymanjournal.com/logo.png https://caymanjournal.com 144 144 # 🧾 What This Document Is This is an Annual Report to Security Holders (ARS). It's a company's "year in review" book sent to shareholders, combining the formal annual report (10-K) with shareholder-friendly visuals, letters, and business highlights. Think of it as the company's curated, investor-fo https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000016 https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000016 Thu, 23 Apr 2026 00:00:00 GMT SEC Filing # 🧾 What This Document Is This is a **DEF 14A**, also called a **proxy statement**. Think of it as an invitation and information packet for the company's annual shareholder meeting. It explains what will be voted on, who is running the company, and how much the top executives are paid. Shareholders https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000014 https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000014 Thu, 23 Apr 2026 00:00:00 GMT SEC Filing # 📰 What This Document Is 📄 This 8-K filing is a Current Report, meaning Inhibrx Biosciences is providing an immediate, detailed update to the public about major developments, specifically clinical trial data. Since the company is developing complex biologics, investors need to know about the prog https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000010 https://caymanjournal.com/stock/INBX/sec-filing/0002007919-26-000010 Tue, 21 Apr 2026 00:00:00 GMT SEC Filing